


PHARMACEUTICAL 2019



Eterna Therapeutics Inc. Rank 182 of 363





PHARMACEUTICAL 2019



Eterna Therapeutics Inc. Rank 182 of 363

The relative strengths and weaknesses of Eterna Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Eterna Therapeutics Inc. compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 160% points. The greatest weakness of Eterna Therapeutics Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 98% points.

The company's Economic Capital Ratio, given in the ranking table, is 101%, being 65% points above the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	6,785
Cost of Goods Sold	0
Intangible Assets	667
Liabilities, Current	4,024
Liabilities, Non-Current	0
Other Assets	2,745
Other Compr. Net Income	-145
Other Expenses	8,582
Other Liabilities	3,923
Other Net Income	-526
Other Revenues	23,335
Property and Equipment	4,667
Research and Development	0
Selling, General and Administrative Expense	14,486

Output Variable	Value in 1000 USD
Assets	14,864
Liabilities	7,947
Expenses	23,068
Revenues	23,335
Stockholders Equity	6,917
Net Income	-259
Comprehensive Net Income	-332
Economic Capital Ratio	101%

